The University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss, offering hope for restoring hearing function.
Charles H. Vite, DVM, PhD from School of Veterinary Medicine at University of Pennsylvania, focuses on a fascinating aspect of neurological disorders concerning developing therapies for cats, dogs & patients.
Dr James E. Goldman, Professor of Pathology and Cell Biology at Columbia University, describes gaining more insight into disease mechanisms by comparing mouse genetic models with the human disease when it comes to Huntington’s Disease.
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.
Isabelle Ote and Valérie Barette, Project Leaders at Belgian immunotherapy expert Imcyse, discuss its next phase of growth, and how to apply ImotopeTM technology to the treatment of MS.
Chris Lynch, Deputy CEO at Alzheimer’s Disease International, sheds light on the WHO Global action plan on the public health response to dementia 2017-2025.
Professor Mogens Hørder, PPI expert, JPND’s management board member and representative of member state Denmark, discusses how Patient and Public Involvement (PPI) is at the heart of neurodegenerative disease research.
Professor Andrew Boulton, President & Professor Akhtar Hussain, President-Elect of the International Diabetes Federation, argue that while there has been a century of saving lives, more must be done to tackle diabetes.
Chief Executive of the Huntington’s Disease Association, Cath Stanley, maps out the charities ongoing work to support its community, despite the COVID-19 pandemic.
Richard Francis, Head of Research at the Stroke Association, identifies the priority areas for research investment that will make the greatest difference to stroke survivors.
Here, Professors Nigel Shrive and John Tyberg illustrate how their work has led to an alternative interpretation of hæmodynamics compared to the paradigm that was proposed over 60 years ago.
